Teva announces launch of authorized generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States.
Teva Pharmaceutical Industries Ltd. announced the launch of the Authorized Generic of Minastrin 24 Fe1 (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the U.S.
The authorized generic of Minastrin 24 Fe is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy. It adds to Teva’s existing portfolio of more than 50 oral contraceptives. In the U.S., one of every two oral contraceptive prescriptions is filled with a product marketed by Teva.2
With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Minastrin 24 Fe had annual sales of approximately $361 million in the U.S. according to IMS data as of December 2016.3
The authorized generic of Minastrin 24 Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by females of reproductive age to prevent pregnancy. Efficacy in women with a body mass index (BMI) of more than 35 kg/m2 has not been evaluated.
1 Minastrin® is a registered trademark of Allergan Pharmaceuticals International Limited.
2 IMS Health NPA data as of November 2016.
3 IMS Health NPA data as of December 2016.
(Source: Business Wire)